Testing the drug tarlatamab with radiation in tumors that make DLL3
Original title: Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, mostly to check how safe the treatment is.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is checking whether a drug called tarlatamab is safe to give along with radiation.
Who this trial is for. This trial is for people with tumors that make a protein called DLL3. It tests giving a drug called tarlatamab together with radiation, first at tumor sites outside the head, and later it may include sites in the head.
Where it stands. The trial is measuring how safe this combination is, including whether the timing of the radiation and the drug changes the side effects. It is also looking at how tumors other than small cell lung cancer respond. The trial has not reported results.
What this means, and what it doesn't
What it could mean: If you have a tumor that makes DLL3 and radiation is part of your care, this study may be worth asking your care team about. They can tell you whether it fits your situation.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.